The pharmacokinetics, tolerability and safety of vessel dilator (VSDL) peptide following subcutaneous infusion to steady state in patients with stable congestive heart failure and moderate renal impairment.
The pharmacokinetics and pharmacodynamics of subcutaneously administered vessel dilator peptide in stable patients with chronic heart failure and moderate renal impairment.
An Exploratory, Single Centre, Open Label, single and Multidose, Safety and Efficacy Study of the Treatment of Acute Decompensated Congestive Heart Failure with Vessel Dilator Peptide by Intravenous Infusion.
100 Clinical Results associated with Madeleine Pharmaceuticals Pty Ltd.
0 Patents (Medical) associated with Madeleine Pharmaceuticals Pty Ltd.
100 Deals associated with Madeleine Pharmaceuticals Pty Ltd.
100 Translational Medicine associated with Madeleine Pharmaceuticals Pty Ltd.